Capital Fund Management S.A. Makes New Investment in Semler Scientific Inc. $SMLR

Key Points

• Capital Fund Management S.A. has invested approximately $1.10 million in Semler Scientific Inc., acquiring 30,461 shares to hold about 0.32% of the company's stock.
• Multiple institutional investors have recently adjusted their stakes in Semler Scientific, with significant increases in holdings from firms like Kovitz Investment Group and NewEdge Advisors.
• Semler Scientific recently reported earnings of $5.04 per share, surpassing analyst estimates, and the company aims to enhance healthcare effectiveness through its QuantaFlo technology.

Capital Fund Management S.A. purchased a new stake in shares of Semler Scientific Inc. (NASDAQ:SMLR - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 30,461 shares of the company's stock, valued at approximately $1,103,000. Capital Fund Management S.A. owned 0.32% of Semler Scientific as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in SMLR. Legal & General Group Plc grew its holdings in shares of Semler Scientific by 65.4% during the 4th quarter. Legal & General Group Plc now owns 2,056 shares of the company's stock worth $111,000 after purchasing an additional 813 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Semler Scientific during the fourth quarter worth $1,939,000. NewEdge Advisors LLC increased its holdings in Semler Scientific by 318.3% in the 4th quarter. NewEdge Advisors LLC now owns 732 shares of the company's stock valued at $40,000 after buying an additional 557 shares during the period. MetLife Investment Management LLC bought a new stake in Semler Scientific in the 4th quarter valued at $163,000. Finally, Stifel Financial Corp raised its stake in shares of Semler Scientific by 107.9% in the 4th quarter. Stifel Financial Corp now owns 52,141 shares of the company's stock valued at $2,816,000 after buying an additional 27,062 shares in the last quarter. Institutional investors and hedge funds own 49.37% of the company's stock.

Wall Street Analyst Weigh In

SMLR has been the topic of a number of analyst reports. Wall Street Zen cut shares of Semler Scientific from a "buy" rating to a "sell" rating in a research note on Thursday, May 22nd. Cantor Fitzgerald decreased their price objective on Semler Scientific from $61.00 to $60.00 and set an "overweight" rating on the stock in a report on Wednesday, August 6th. Benchmark began coverage on Semler Scientific in a report on Tuesday, July 8th. They issued a "buy" rating and a $101.00 target price for the company. Finally, Maxim Group raised Semler Scientific to a "strong-buy" rating and set a $95.00 price target on the stock in a research note on Wednesday, July 9th. One investment analyst has rated the stock with a Strong Buy rating and three have issued a Buy rating to the stock. Based on data from MarketBeat.com, Semler Scientific has a consensus rating of "Buy" and an average price target of $81.75.

Semler Scientific Price Performance

SMLR stock traded up $0.07 during midday trading on Thursday, reaching $30.63. 641,343 shares of the company's stock traded hands, compared to its average volume of 568,305. The company has a 50-day simple moving average of $37.47 and a two-hundred day simple moving average of $37.39. The company has a quick ratio of 0.58, a current ratio of 0.60 and a debt-to-equity ratio of 0.25. Semler Scientific Inc. has a 1-year low of $21.77 and a 1-year high of $81.56. The company has a market cap of $453.63 million, a price-to-earnings ratio of 12.60 and a beta of 1.34.

Semler Scientific (NASDAQ:SMLR - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $5.04 EPS for the quarter, topping the consensus estimate of ($0.27) by $5.31. The company had revenue of $8.22 million for the quarter, compared to analysts' expectations of $8.10 million. Semler Scientific had a return on equity of 43.84% and a net margin of 86.20%.

Semler Scientific Profile

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition.